Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- IBL Launches ANGPTL2 Assay Kit
October 17, 2011
- 60% Rule Likely to Replace 70% Rule for New Generics: Mr Kikuchi of Nichi-Iko MPI
October 17, 2011
- Otsuka Medical Devices to Acquire KiSCO Group Companies
October 17, 2011
- CMIC Forms a Chinese Joint Venture, Making Capital Investment in Local CRO
October 14, 2011
- Nichi-Iko to Be Delisted from OSE, NSE
October 14, 2011
- Nichi-Iko Revises Full-year Forecasts Downward Despite Double-digit Growth in Sales
October 14, 2011
- Daiichi Sankyo Resubmits NDA for Iron Deficiency Anemia Treatment Injectafer to FDA
October 14, 2011
- Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
- Nihon Chouzai Aims to Triple Home Healthcare, Nursing Facility Business in 2 Years
October 14, 2011
- Eli Lilly Japan Applies for Strattera for AD/HD in Adults
October 13, 2011
- Hisamitsu Posts 2.7% Loss in Mar-Aug Results on Shipping Adjustments of Main Products
October 13, 2011
- Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
- Hisamitsu: Sales of Norspan Lower Than Expected
October 13, 2011
- CHMP Recommends Approval of Novo’s Levemir for Type I Diabetes in Children
October 13, 2011
- Asahi Kasei Pharma to Start Clinical Trials in 2012 of US Transdermal Patch Formulation
October 12, 2011
- NanoCarrier, France’s LFB Agree on Joint Research Agreement
October 12, 2011
- MediciNova Gets Approval for Chinese Joint Venture
October 12, 2011
- PIII Study of Rivaroxaban in Patients with ACS to be Presented at AHA Congress: Bayer
October 12, 2011
- Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
- AZ to Invest $200 Mil. to Build New Factory in China
October 12, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…